Advanced therapies in Parkinson’s Disease
In cutting edge Parkinson's malady (PD), neurologists and patients confront an unpredictable choice for a propelled treatment. While picking a treatment, the best accessible proof ought to be joined with the expert's skill and the patient's inclinations. Objective: The target of this investigation was to investigate current basic leadership in cutting edge PD. Techniques: We led centre gathering exchanges and individual meetings with patients (N = 20) who had gotten profound cerebrum incitement, Levodopa-Carbidopa intestinal gel, or subcutaneous Apo morphine implantation, and with their guardians (N = 16).
- Gene therapy
- Neural Degeneration
- Neuturin Gene Therapy for Parkinson’s disease
- Surgical therapeutics for Parkinson’s disease
- Neurotrophic Factor
Related Conference of Advanced therapies in Parkinson’s Disease
June 22-23, 2026
18th Global Neurologists Meeting on Neurology and Neurosurgery
Amsterdam, Netherlands
June 29-30, 2026
31st International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences
Paris, France
July 20-21, 2026
11th International Conference on Central Nervous System Disorders & Therapeutics
Amsterdam, Netherlands
July 23-24, 2026
14th International Conference on Cannabis & Medicinal Research
Amsterdam, Netherlands
September 17-18, 2026
31st Global Experts Meeting on Neuroscience and Neuropharmacology
Paris, France
April 27-28, 2027
18th International Conference on Stroke, Neurology and Cerebrovascular Diseases
Paris, France